News | August 13, 2021
Wockhardt to manufacture and supply Sputnik V
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
Demand normalisation post the second wave contributed to the steady growth
Income declines marginally
It’s an AB-rated generic therapeutic version of Durezol
It plays a pivotal role in monitoring pharmaceutical pricing
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Subscribe To Our Newsletter & Stay Updated
